eligibility_summary
Adults ≥18 with metastatic castration‑resistant prostate adenocarcinoma (no NE/small cell), PSA ≥1, progression within 6 mo (RECIST/bone scan or PSMA+PSA). Prior NHA and taxane (unless ineligible/refuse), BRCA: prior PARPi, MSI‑H/dMMR: prior checkpoint (or ineligible). ECOG 0–1, life expectancy >12 wk, adequate organs, provide tumor tissue/biopsies. Exclude: <39 kg, brain mets/transplant, cardiac/QT/neuro issues, uncontrolled illness/infection/autoimmune, prior CAR‑T/STEAP2, allergy, AU: HTLV
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Interventions: 1) AZD0754, an autologous CAR T-cell therapy (biologic, genetically modified T cells) targeting STEAP2, a prostate tumor surface antigen. Mechanism: patient T cells are engineered to express a STEAP2-specific CAR, upon binding STEAP2 on cancer cells, CAR signaling (CD3ζ/co-stimulation) triggers T-cell activation, proliferation, cytokine release, and cytolytic killing of STEAP2-positive metastatic prostate cancer. Administered IV after lymphodepleting chemotherapy. 2) AZD2287, an optional STEAP2-targeted radioactive imaging agent (biologic radiotracer) used with SPECT/CT to visualize STEAP2 expression and biodistribution. Cells/pathways targeted: STEAP2-expressing prostate tumor cells, autologous T lymphocytes via CAR activation, immune effector pathways (immune synapse, perforin/granzyme, cytokines).